Vivani Medical Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Core Insights - Vivani Medical, Inc. has successfully completed its first-in-human study LIBERATE-1 for the NPM-139 semaglutide implant, which is aimed at chronic weight management, with results expected by the end of 2026 [1][4][16] - The company has demonstrated over 20% sham-adjusted weight loss sustained for a full year with a single preclinical administration of the semaglutide implant [1][4][5] - Vivani's financial position is solid, with $41.5 million raised in gross proceeds from various financings, expected to support operations into mid-2027 [2][8] Company Developments - The company is advancing its NPM-139 semaglutide implant based on positive results from LIBERATE-1 and preclinical studies, with plans to initiate a Phase 1 clinical study in mid-2026 [5][6] - Vivani's CEO highlighted the unique features of their GLP-1 implant candidates, including the potential for annual dosing and the ability to quickly cease treatment if necessary [4] - Significant progress has been made in manufacturing capabilities, preparing for commercial-scale production [4] Financial Performance - As of December 31, 2025, Vivani reported cash and cash equivalents of $16.2 million, down from $18.4 million in 2024, primarily due to a net loss of $26.6 million [11][19] - Research and development expenses for Q4 2025 were $4.6 million, a 7% increase from $4.3 million in Q4 2024, attributed to staffing reductions and decreased use of outside services [12] - The net loss for the full year 2025 was $26.6 million, compared to $23.5 million in 2024, reflecting increased clinical trial and development expenses [19] Upcoming Milestones - The company anticipates the initiation of the Phase 1 feasibility study for NPM-139 in mid-2026, with data potentially available by the end of the year [4][6][16] - Plans are in place for a Phase 2 clinical study of NPM-139, pending results from the Phase 1 study and regulatory feedback [6]